Teleflex price target lowered to $142 from $150 at Truist
Truist analyst Richard Newitter lowered the firm’s price target on Teleflex (TFX) to $142 from $150 and keeps a Hold rating on the shares as part of a broader research…
Fiscal Year: January - December
Teleflex Incorporated (TFX), listed on the NYSE, has a market capitalization of $5.53B. As of Oct 22, 2026, the stock is trading at $130.40 per share@else an unavailable price , offering investors a clear view of its current market value. Teleflex Incorporated is a prominent player in the industry sector, attracting both institutional and retail investors due to its performance and potential.
With a P/E ratio of 92.95, investors can assess the stock's valuation in comparison to its earnings. A P/E ratio is a crucial indicator for value investors, showing whether the stock is over or undervalued relative to its current earnings. Teleflex Incorporated also offers a dividend yield of 1.04%, making it an attractive option for income-focused investors who seek regular dividends.
Our Discounted Cash Flow (DCF) analysis reveals that Teleflex Incorporated (TFX) has a DCF fair value that is only shown to premium members. To see it, please Login or Upgrade for access.
The proprietary SS Score for Teleflex Incorporated is a unique metric that analyzes the company's financial health and growth potential. The score takes into account critical factors such as revenue growth, net income, free cash flow (FCF) compound annual growth rate (CAGR), the trend of shares outstanding, and the debt-to-FCF ratio. This helps investors to make a more informed decision, as an undervalued stock might still have poor financial fundamentals.
To view the detailed SS Score for Teleflex Incorporated, Login or Upgrade for access.
The Price to Free Cash Flow (P/FCF) ratio for Teleflex Incorporated is 16.89, offering insights into how much investors are paying for the company's free cash flow. A lower P/FCF ratio typically suggests that the stock is undervalued, while a higher ratio may indicate overvaluation.
In summary, Teleflex Incorporated (TFX) has shown consistent financial performance, as illustrated by the financial charts above, which track its revenue growth, net income, free cash flow, and shares outstanding over the past several years. These metrics provide investors with key insights into the company's past and projected future performance. Investors should use the SS Score alongside the DCF Fair Value to make better-informed decisions about whether to buy or hold the stock.
*This analysis is for informational purposes only and does not constitute investment advice. Always read the company's 10-K filings and do your own research before making any investment decisions.
Whether Teleflex Incorporated (TFX) is a good stock to buy depends on various factors, including its financial health, market conditions, and your investment strategy. It is important to assess the SS Score and review the company's fundamentals before making any investment decisions.
The fair value of Teleflex Incorporated (TFX) is determined through our Discounted Cash Flow (DCF) analysis. This value represents the intrinsic worth of the stock based on its expected future cash flows. To view the specific fair value, consider subscribing to our service for complete access.
The SS Score is a proprietary financial quality metric that assesses factors such as revenue growth, net income, free cash flow growth, and debt levels. It helps investors evaluate the overall financial health of Teleflex Incorporated. To access the full SS Score, consider upgrading your subscription.
Teleflex Incorporated is a significant player in the industry sector, with a market capitalization of $5.53B and a competitive P/E ratio of 92.95. Investors should compare these metrics with industry peers to gauge whether Teleflex Incorporated is outperforming or underperforming within its sector.
Truist analyst Richard Newitter lowered the firm’s price target on Teleflex (TFX) to $142 from $150 and keeps a Hold rating on the shares as part of a broader research…
Mizuho lowered the firm’s price target on Teleflex (TFX) to $140 from $145 and keeps a Neutral rating on the shares. The firm adjusted targets in the medical devices and…
Teleflex (TFX) Iannounced the successful completion of patient enrollment in the BIOMAG-LL Clinical Study, evaluating the safety and clinical performance of the Freesolve Resorbable Magnesium Scaffold...
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the successful completion of patient enrollment in the BIOMAG™-LL Cli...
Teleflex (TFX) announced the publication of its latest peer-reviewed study in the American Journal of Infection Control demonstrating that Central Venous Catheters, or CVCs, protected with Arrowg+ard ...
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced the publication of its latest peer-reviewed study in the American Jou...
As previously reported, BofA analyst Travis Steed upgraded Teleflex (TFX) to Buy from Neutral with a price target of $158, up from $145. With a new management team and better…
BofA upgraded Teleflex (TFX) to Buy from Neutral with a price target of $158, up from $145.
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced the appointment of Sean M. Salmon to its Board of Directors, effective...
Teleflex (TFX) announced it will showcase technologies at CIRSE 2026 in Copenhagen. Among the featured technologies will be the Dynetic-35 Balloon-Expandable Cobalt Chromium Stent System. This technol...
Teleflex (TFX) Incorporated announced it will showcase technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technol...
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen,...
UBS raised the firm’s price target on Teleflex (TFX) to $158 from $145 and keeps a Neutral rating on the shares. The firm updated its model post the Q2 earnings…
Truist analyst Richard Newitter raised the firm’s price target on Teleflex (TFX) to $150 from $143 and keeps a Hold rating on the shares after its Q2 earnings beat. A…
Raymond James raised the firm’s price target on Teleflex (TFX) to $155 from $150 and keeps an Outperform rating on the shares. Teleflex delivered solid Q2 results, raised EPS guidance,…
2026 EPS consensus $6.67. Lowers 2026 revenue growth view to 13.4%-14.4% from 14.4%-15.4% from 2025 revenue of $1.98B, consensus $2.29B.
Reports Q2 cont-op revenue $570.3M, consensus $559.57M. “We delivered a strong Q2, led by excellent performance in our Vascular and Surgical businesses, while continuing to take decisive actions to st...
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. Th...
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) (the “Company”) today announced financial results for the second quarter ended June 30, 2026. Second quarter 2026 continuing operations f...
Combining leading in-house expertise with platform-enhancing investments to accelerate advances in engineering, innovation and manufacturing capabilities serving global medical device innovators Marks...
WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, today announced it has completed the previously disclosed divestiture of its OEM busin...
Projected from reported cash flow (SEC filings). The starting point is the latest yearly revenue times the median free cash flow margin of the last five years. Years 1 to 5 grow at the revenue growth rate of the last five years (between -5% and 15%), and years 6 to 10 slow down to the 2.5% perpetual growth rate. These are Studying Stocks' own estimates, not analyst forecasts, and are intended for educational purposes only as a baseline for the analysis.
| Year | FCF Estimate | % | Source |
|---|---|---|---|
| 2026 | 390.67M | -5.00% | Projected |
| 2027 | 371.14M | -5.00% | Projected |
| 2028 | 352.58M | -5.00% | Projected |
| 2029 | 334.95M | -5.00% | Projected |
| 2030 | 318.20M | -5.00% | Projected |
| 2031 | 307.06M | -3.50% | Projected |
| 2032 | 300.92M | -2.00% | Projected |
| 2033 | 299.42M | -0.50% | Projected |
| 2034 | 302.41M | 1.00% | Projected |
| 2035 | 309.97M | 2.50% | Projected |
Below are the FCF estimates with the discount factor and the calculated present value with the terminal value that led the results above.
| Year | FCF | Discount Factor | PV of Future FCF |
|---|---|---|---|
| 2024A | 545.30M | 1.00 | 545.30M |
| 2025A | 245.44M | 1.00 | 245.44M |
| 2026E | 390.67M | 1.08 | Login |
| 2027E | 371.14M | 1.17 | Login |
| 2028E | 352.58M | 1.26 | Login |
| 2029E | 334.95M | 1.36 | Login |
| 2030E | 318.20M | 1.47 | Login |
| 2031E | 307.06M | 1.59 | Login |
| 2032E | 300.92M | 1.72 | Login |
| 2033E | 299.42M | 1.86 | Login |
| 2034E | 302.41M | 2.01 | Login |
| 2035E | 309.97M | 2.17 | Login |
| Terminal | 2.17 | Login |
The information given by Studying Stocks and provided in the web and/or mobile applications (Platforms) is only factual information and should not be considered financial advice.
Any information contained in this website has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
When creating an account, you acknowledge that you are:
We retain the right to cancel your account for any reason, or refuse your account creation request.
The information on our Platforms is not comprehensive and is intended to provide a summary of the subject matter covered. While we use all reasonable attempts to ensure the accuracy and completeness of the data and information on our Platforms, to the extent permitted by law, we make no warranty regarding the information on these Platforms. You should monitor any changes to the information contained on these Platforms.
Furthermore we make no commitments in regards to the minimum amount of uptime that our platforms will maintain, although we will make ever reasonable attempt to ensure that the platforms are operational. Therefore, any reference of "latest", "current" and related words about the financial data presented here may not be up to date with the financial markets or represent reality of the information.
We are not liable to you or anyone else if interference with or damage to your computer systems occurs in connection with the use of these Platforms or a linked website. You must take your own precautions to ensure that whatever you select for your use from our Platforms is free of viruses or anything else (such as worms or Trojan horses) that may interfere with or damage the operations of your computer systems.
We may, from time to time and without notice, change or add to the Platforms (including the Terms) or the information, products or services described in it. However, we do not undertake to keep the Platforms updated. We are not liable to you or anyone else if errors occur in the information or the Platforms is not up-to-date.
Our Platforms may contain links to websites operated by third parties. Those links are provided for convenience and may not remain current or be maintained. Unless expressly stated otherwise, we do not endorse and are not responsible for the content on those linked websites and have no control over or rights in those linked websites.
These Platforms are for your personal, non-commercial use only. You may not modify, copy, distribute, transmit, display, perform, reproduce, publish, license, commercially exploit, create derivative works from, transfer, or sell any Content, software, products or services contained within these Platforms. You may not use these Platforms, or any of its Content, to further any commercial purpose, including any advertising or advertising revenue generation activity on your own website.
You must not do any act that we would deem to be inappropriate, is unlawful or is prohibited by any laws applicable to these Platforms, including but not limited to:
If we allow you to post any information to our Platforms, we have the right to take down this information at our sole discretion and without notice.
To the maximum extent permitted by law, we make no warranties or representations about these Platforms or the Content, including but not limited to warranties or representations that they will be complete, accurate or up-to-date, that access will be uninterrupted or error-free or free from viruses, or that these Platforms will be secure.
We reserve the right to restrict, suspend or terminate without notice your access to these Platforms, any Content, or any feature of these Platforms at any time without notice and we will not be responsible for any loss, cost, damage or liability that may arise as a result.
To the maximum extent permitted by law, in no event shall we be liable for any direct and indirect loss, damage or expense – irrespective of the manner in which it occurs – which may be suffered due to your use of our Platforms and/or the information or materials contained on it, or as a result of the inaccessibility of these Platforms and/or the fact that certain information or materials contained on it are incorrect, incomplete or not up-to-date.
This website utilises cookies. If you do not have cookies enabled in your web browser some functions of the site may not work as intended.